Skip to main content

Table 4 Characteristics of patients in remission (n = 21)

From: Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study

Characteristic
Time to Remission (weeks)  
   Mean (SD) 21.1 (12.7)
   Median 24
   Range 4, 34
Time in Absolute Sustained Remission (weeks)a  
   Mean (SD) 22.5 (7.5)
   Median 25
   Range 6, 30
Dose at Remissionb  
   20 mg, n (%) 5 (23.8)
   30 mg, n (%) 2 (9.5)
   35 mg, n (%) 4 (19.0)
   40 mg, n (%) 2 (9.5)
   50 mg, n (%) 8 (38.1)
Dose at the 32-week visit (prior to tapering)  
   20 mg, n (%) 5 (23.8)
   30 mg, n (%) 3 (14.3)
   35 mg, n (%) 4 (19.0)
   40 mg, n (%) 1 (4.8)
   50 mg, n (%) 8 (38.1)
Dose whilst in remission, mgc  
   Mean (SD) 30.7 (11.0)
   Median 30
   Range 10, 50
  1. a Dose at remission is taken as the dose at first achieving absolute sustained remission for patients achieving absolute sustained remission, and the dose at the 32-week visit for those patients not achieving absolute sustained remission.
  2. b Time in absolute sustained remission is taken as the difference between the 34-week visit and the week of first achieving absolute sustained remission for patients achieving absolute sustained remission, and as 0 weeks for patients not achieving absolute sustained remission.
  3. c The dose of all episodes of remission i.e. a MADRS score of ≤8